[go: up one dir, main page]

EA201590027A1 - Способы детекции заболеваний или состояний - Google Patents

Способы детекции заболеваний или состояний

Info

Publication number
EA201590027A1
EA201590027A1 EA201590027A EA201590027A EA201590027A1 EA 201590027 A1 EA201590027 A1 EA 201590027A1 EA 201590027 A EA201590027 A EA 201590027A EA 201590027 A EA201590027 A EA 201590027A EA 201590027 A1 EA201590027 A1 EA 201590027A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
conditions
detection methods
methods
relates
Prior art date
Application number
EA201590027A
Other languages
English (en)
Inventor
Гарри Стилли
Original Assignee
Гарри Стилли
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гарри Стилли filed Critical Гарри Стилли
Publication of EA201590027A1 publication Critical patent/EA201590027A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

Abstract

Настоящее изобретение относится к способам использования образца с множеством аналитических компонентов в диагностике, прогнозе или мониторировании заболеваний или состояний. Изобретение также относится к способам идентификации маркеров заболеваний или состояний.
EA201590027A 2012-06-15 2013-06-14 Способы детекции заболеваний или состояний EA201590027A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261660427P 2012-06-15 2012-06-15
PCT/US2013/046020 WO2013188846A1 (en) 2012-06-15 2013-06-14 Methods of detecting diseases or conditions

Publications (1)

Publication Number Publication Date
EA201590027A1 true EA201590027A1 (ru) 2015-05-29

Family

ID=49758768

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590027A EA201590027A1 (ru) 2012-06-15 2013-06-14 Способы детекции заболеваний или состояний

Country Status (13)

Country Link
US (3) US20140179805A1 (ru)
EP (1) EP2861765B1 (ru)
JP (1) JP2015522260A (ru)
KR (1) KR20150035821A (ru)
CN (1) CN104603289A (ru)
AU (1) AU2013274002A1 (ru)
BR (1) BR112014031365A2 (ru)
CA (1) CA2876731A1 (ru)
EA (1) EA201590027A1 (ru)
IL (1) IL236181A0 (ru)
MX (1) MX2014015425A (ru)
SG (2) SG11201408385TA (ru)
WO (1) WO2013188846A1 (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
WO2014164366A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting cancer
US20150260631A1 (en) * 2014-03-17 2015-09-17 Health Diagnostic Laboratory, Inc. System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions
JP6297676B2 (ja) 2013-05-06 2018-03-20 日立化成株式会社 標的分子を捕捉するためのデバイス及び方法
US10450620B2 (en) 2013-11-07 2019-10-22 The Board Of Trustees Of The Leland Stanford Junior University Cell-free nucleic acids for the analysis of the human microbiome and components thereof
WO2015095359A1 (en) * 2013-12-17 2015-06-25 Harry Stylli Methods of detecting diseases or conditions
EP3161482B1 (en) * 2014-06-27 2020-08-26 XY Evergreen Technology Company Method for enriching cns-derived exosomes
EP3164506A4 (en) * 2014-07-01 2018-02-28 Mayo Foundation for Medical Education and Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
WO2016040843A1 (en) * 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
CN105525033A (zh) * 2014-09-29 2016-04-27 天津华大基因科技有限公司 检测血液中微生物的方法及装置
US10266895B2 (en) 2014-11-05 2019-04-23 Hitachi Chemical Company Ltd. Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
JP6631852B2 (ja) * 2014-11-12 2020-01-15 日立化成株式会社 臓器障害を診断するための方法および装置
US11242559B2 (en) 2015-01-13 2022-02-08 The Chinese University Of Hong Kong Method of nuclear DNA and mitochondrial DNA analysis
GB2555921B (en) 2015-03-06 2021-09-15 Micromass Ltd Endoscopic tissue identification tool
CN107646089B (zh) 2015-03-06 2020-12-08 英国质谱公司 光谱分析
CA2978165A1 (en) 2015-03-06 2016-09-15 Micromass Uk Limited Improved ionisation of gaseous samples
US10026599B2 (en) 2015-03-06 2018-07-17 Micromass Uk Limited Rapid evaporative ionisation mass spectrometry (“REIMS”) and desorption electrospray ionisation mass spectrometry (“DESI-MS”) analysis of swabs and biopsy samples
EP3726562B1 (en) 2015-03-06 2023-12-20 Micromass UK Limited Ambient ionization mass spectrometry imaging platform for direct mapping from bulk tissue
EP3265822B1 (en) 2015-03-06 2021-04-28 Micromass UK Limited Tissue analysis by mass spectrometry or ion mobility spectrometry
US11342170B2 (en) 2015-03-06 2022-05-24 Micromass Uk Limited Collision surface for improved ionisation
EP4365928A3 (en) 2015-03-06 2024-07-24 Micromass UK Limited Spectrometric analysis of microbes
CN108700590B (zh) 2015-03-06 2021-03-02 英国质谱公司 细胞群体分析
WO2016187234A1 (en) 2015-05-18 2016-11-24 Karius, Inc. Compositions and methods for enriching populations of nucleic acids
CN105037553B (zh) * 2015-08-20 2018-04-17 内蒙古蒙元生物基因科技有限公司 一种能够检测癌症的免疫球蛋白
CN106467926A (zh) * 2015-08-20 2017-03-01 北京京爱康科技有限公司 一种定位目标表型癌细胞中表型基因的方法
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
CN105132575B (zh) * 2015-09-28 2020-03-27 固安博健生物技术有限公司 骨质疏松症的分子标志物及其应用
GB201517195D0 (en) 2015-09-29 2015-11-11 Micromass Ltd Capacitively coupled reims technique and optically transparent counter electrode
CN105132429A (zh) * 2015-10-10 2015-12-09 华东理工大学 靶向人KPNB1基因的siRNA及其应用
WO2017148432A1 (zh) * 2016-03-04 2017-09-08 厦门大学 用于预测慢性乙肝患者对IFNα治疗的应答的方法和试剂盒
BR112018069557A2 (pt) 2016-03-25 2019-01-29 Karius Inc spike-ins de ácido nucléico sintético
EP3443354B1 (en) 2016-04-14 2025-08-20 Micromass UK Limited Spectrometric analysis of plants
IL262794B2 (en) * 2016-05-10 2023-10-01 Univ Nat Corp Tokyo Medical & Dental Expression inhibitor of inflammation promoting factor, screening method for active ingredient thereof, expression cassette useful for said method, diagnostic agent and diagnosis method
CN106018372B (zh) * 2016-07-19 2018-06-05 济南大学 双功能复合探针构建荧光/比色双模MiRNA传感器
ES2971214T3 (es) 2016-09-02 2024-06-04 Univ Texas Sonda de recolección y métodos para su uso
CN106636366A (zh) * 2016-11-25 2017-05-10 苏州首度基因科技有限责任公司 预测胃癌转移的基因检测试剂盒及其使用方法
US10697008B2 (en) 2017-04-12 2020-06-30 Karius, Inc. Sample preparation methods, systems and compositions
CN110462064A (zh) * 2017-04-18 2019-11-15 深圳华大生命科学研究院 基于外泌体核酸进行微生物检测的方法及其应用
CN107475366B (zh) * 2017-07-03 2020-04-28 博尔诚（北京）科技有限公司 一种用于检测疾病的组合物及其试剂盒和用途
US11685951B2 (en) 2017-07-18 2023-06-27 The Research Foundation For The State University Of New York Biomarkers for intracranial aneurysm
CN107563069A (zh) * 2017-09-06 2018-01-09 国电联合动力技术有限公司 一种风力发电机组故障智能诊断方法
JP7376873B2 (ja) 2017-11-09 2023-11-09 国立大学法人 東京医科歯科大学 がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
MX2020005448A (es) 2017-11-27 2020-08-27 Univ Texas Sonda de recoleccion minimamente invasiva y metodos para el uso de esta.
CN108300716B (zh) * 2018-01-05 2020-06-30 武汉康测科技有限公司 接头元件、其应用和基于不对称多重pcr进行靶向测序文库构建的方法
CN108384840A (zh) * 2018-01-24 2018-08-10 安徽微分基因科技有限公司 一种口腔拭子无提取tp53snp基因分型方法
GB201803553D0 (en) * 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
JP7469584B2 (ja) 2018-06-20 2024-04-17 東ソー株式会社 抗体の分離方法および疾患の検査方法
WO2020051530A1 (en) * 2018-09-07 2020-03-12 Juneau Biosciences, L.L.C. Methods of using genetic markers associated with endometriosis
KR20200048740A (ko) 2018-10-30 2020-05-08 (주)아모레퍼시픽 Dnaja1 발현 촉진 물질을 포함하는 피부 장벽기능 강화용 조성물 및 dnaja1 촉진 물질의 스크리닝 방법
EP4428234A3 (en) 2018-11-21 2024-09-25 Karius, Inc. Direct-to-library methods, systems, and compositions
CN109371123B (zh) * 2018-12-24 2022-06-17 中国医学科学院北京协和医院 用于检测自身炎症性疾病致病基因的探针组及试剂盒
CN113853443A (zh) * 2019-03-08 2021-12-28 株式会社Neogentc 用于预测淋巴细胞的肿瘤反应性的标志物及其用途
EP3948293A4 (en) * 2019-04-04 2022-12-28 Magarray, Inc. METHODS FOR THE PRODUCTION OF CIRCULATION ANALYTICAL PROFILES AND DEVICES FOR THEIR IMPLEMENTATION
KR102427319B1 (ko) * 2019-08-16 2022-08-01 더 차이니즈 유니버시티 오브 홍콩 핵산의 염기 변형의 결정
WO2021041931A1 (en) * 2019-08-28 2021-03-04 The Regents Of The University Of California Methods of producing dna methylation profiles
KR20220084305A (ko) * 2019-10-04 2022-06-21 더 리젠츠 오브 더 유니버시티 오브 미시간 건선의 치료에서 항-종양 괴사 인자 치료법에 대한 반응성을 결정하는 방법
KR102376945B1 (ko) * 2019-12-19 2022-03-21 상지대학교산학협력단 파킨슨병용 약제학적 조성물 및 그 치료제
CA3172199A1 (en) * 2020-03-18 2021-09-23 Michael Nerenberg Systems and methods of detecting a risk of alzheimer's disease using a circulating-free mrna profiling assay
CN113913424B (zh) * 2020-07-09 2023-08-08 四川大学华西医院 一种腺相关病毒及其制备在治疗可卡因成瘾的药物中的用途
KR102400464B1 (ko) * 2020-07-28 2022-05-19 부산대학교 산학협력단 암 줄기세포 검출용 바이오 마커 조성물
CN111679018B (zh) * 2020-08-14 2020-11-20 宝枫生物科技（北京）有限公司 用于诊断认知障碍的生物标记物及其应用
CN112415198B (zh) * 2020-11-20 2022-11-11 四川大学华西医院 Gp1bb检测试剂在制备肺癌筛查试剂盒中的用途
CN112843222B (zh) * 2021-01-21 2023-01-31 暨南大学 Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
CN113075399B (zh) * 2021-03-29 2021-09-21 广州市妇女儿童医疗中心 抗单链dna抗体作为先天性巨结肠诊断标志物的应用
EP4413153A1 (en) * 2021-10-08 2024-08-14 Waters Technologies Corporation Sample preparation for lc-ms based sequence mapping of nucleic acids
EP4472667A2 (en) * 2022-02-03 2024-12-11 The Brigham & Women's Hospital, Inc. Companion diagnostic for human ceacam1 directed therapeutic agents
CN118986863A (zh) * 2024-10-18 2024-11-22 四川新泌学生物科技有限公司 一种外阴用外泌体凝胶及其制备方法

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
GB0104690D0 (en) 2001-02-26 2001-04-11 Cytogenetic Dna Services Ltd Diagnostic test
FR2824144B1 (fr) * 2001-04-30 2004-09-17 Metagenex S A R L Methode de diagnostic prenatal sur cellule foetale isolee du sang maternel
DE10291986D2 (de) 2001-05-09 2004-04-15 Biovision Ag Verfahren zum Nachweis einer progredienten, chronisch-demenziellen Erkrankung, zugehörige Peptide und Nachweisreagenzien
JP2006508632A (ja) * 2002-03-01 2006-03-16 ラブジェン， インコーポレイテッド 遺伝子疾患の検出法
AU2003246380A1 (en) 2002-07-05 2004-01-23 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases
FR2844279A1 (fr) 2002-09-06 2004-03-12 Inst Nat Sante Rech Med Moyens de detection des processus neurodegeneratifs et leurs applications
GB0225360D0 (en) 2002-10-31 2002-12-11 Univ London Genetic markers
WO2004070388A1 (en) 2003-02-04 2004-08-19 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
JP2006518214A (ja) 2003-02-13 2006-08-10 株式会社インテレクチャル・プロパティ・コンサルティング 神経障害および疾患の診断および処置のための遺伝子マーカー、組成物およびその利用
WO2005033341A2 (en) 2003-10-03 2005-04-14 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of cripto-1 as a biomarker for neurodegenerative disease and method of inhibiting progression thereof
EP1685410A1 (en) 2003-11-19 2006-08-02 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of the human sgpl1 gene and protein for neurodegenerative diseases
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
EP2211183B1 (en) 2003-11-19 2013-03-06 Satoris, Inc. Method for diagnosis and monitoring of Alzheimer's disease
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
WO2005075674A1 (en) 2004-02-04 2005-08-18 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of kcne4 gene and protein for alzheimer disease
US20080051334A1 (en) 2004-04-16 2008-02-28 Evotec Neurosciences Gmbh Diagnostic and Therapeutic Use of Kcnc1 for Neurodegenerative Diseases
US7838245B2 (en) 2004-04-20 2010-11-23 Sphingotec Gmbh Use of precursors of tachykinins and/or their fragments in medical diagnostic
WO2005108582A1 (en) 2004-05-07 2005-11-17 Garvan Institute Of Medical Research DETECTING DISEASE ASSOCIATION WITH ABERRANT GLYCOGEN SYNTHASE KINASE 3β EXPRESSION
EP1745296A2 (en) 2004-05-10 2007-01-24 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of kcnj6 for alzheimer's disease
DE602005026931D1 (de) 2004-05-13 2011-04-28 Brahms Gmbh Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik
CN1981196B (zh) 2004-05-19 2012-10-03 哥本哈根大学 Adam12，一种细胞功能异常的新标记物
CA2574727A1 (en) 2004-07-19 2006-02-23 University Of Rochester Biomarkers of neurodegenerative disease
EP1778874B1 (en) 2004-07-30 2011-11-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for cervical cancer
US20070087376A1 (en) 2004-08-30 2007-04-19 Potashkin Judith A Splice variants of pre-mRNA transcripts as biomarkers in idiopathic neurodegenerative diseases
WO2006050475A2 (en) 2004-11-03 2006-05-11 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with neurological diseases
WO2006048778A1 (en) 2004-11-08 2006-05-11 King's College London Markers of predisposition to addictive states
US20060115855A1 (en) 2004-12-01 2006-06-01 Power3 Medical Products, Inc. FK506-binding protein 7 related protein as a biomarker for neurodegenerative disease
US20060115854A1 (en) 2004-12-01 2006-06-01 Power3 Medical Products, Inc. Acetyl-LDL receptor related proteins and peptides as a biomarker for neurodegenerative disease
GB0426859D0 (en) 2004-12-07 2005-01-12 Proteome Sciences Plc Diagnosis of neurodegenerative disorders
EP1825275B1 (en) 2004-12-07 2010-06-16 Electrophoretics Limited Diagnosis of neurodegenerative diseases
US7572592B2 (en) 2005-01-31 2009-08-11 Glycominds Ltd Method for diagnosing multiple sclerosis
US20070141625A1 (en) 2005-02-03 2007-06-21 Santos Jose H Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies
AU2006224971B2 (en) * 2005-03-18 2009-07-02 Boston University A method for the detection of chromosomal aneuploidies
DE602006014379D1 (de) 2005-04-06 2010-07-01 Klinik Und Poliklinik Fuer Psy Neurodegenerative marker für depression.
GB0512401D0 (en) 2005-06-17 2005-07-27 Randox Lab Ltd Method
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US20070148661A1 (en) 2005-07-19 2007-06-28 Duke University LSAMP Gene Associated With Cardiovascular Disease
CN100410663C (zh) * 2005-09-11 2008-08-13 翁炳焕 蛋白质组的分析方法
EP1987361A4 (en) 2006-01-30 2009-03-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
US8304246B2 (en) 2006-02-28 2012-11-06 Phenomenome Discoveries, Inc. Methods for the diagnosis of dementia and other neurological disorders
EP1847615A1 (en) 2006-04-18 2007-10-24 Genoscreen Expression and polymorphism of the ornithine transcarbamylase (OTC) gene as markers for diagnosing Alzheimer's disease
US20090305265A1 (en) 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
AU2007248160B2 (en) 2006-05-01 2011-03-24 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
WO2007131345A1 (en) 2006-05-12 2007-11-22 The Hospital For Sick Children Genetic risk factor in sod1 and sfrs15 in renal disease, diabetic cataract, cardiovascular disease and longevity
ES2429225T3 (es) 2006-05-17 2013-11-13 The Ludwig Institute For Cancer Research Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
US20100009352A1 (en) 2006-05-24 2010-01-14 Gough Albert H Method for Modeling a Disease
DE102006027818A1 (de) 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
WO2008003826A1 (en) 2006-07-07 2008-01-10 Oy Jurilab Ltd Novel genes and markers in essential arterial hypertension
KR100856375B1 (ko) 2006-07-18 2008-09-04 김현기 퇴행성 신경질환 진단용 마커
US7851172B2 (en) 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
WO2008014516A2 (en) 2006-07-28 2008-01-31 Living Microsystems, Inc. Selection of cells using biomarkers
WO2008028257A1 (en) 2006-09-08 2008-03-13 Garvan Institute Of Medical Research Diagnostics and therapeutics of neurological disease
US20090318354A1 (en) 2006-09-26 2009-12-24 Proteosys Ag Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
EP2118135A1 (en) 2006-10-16 2009-11-18 Bayer Schering Pharma AG Crtac as a biomarker, therapeutic and diagnostic target
WO2008046509A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Ltbp2 as a biomarker, therapeutic and diagnostic target
US20100104501A1 (en) 2006-10-16 2010-04-29 Stefan Golz Prss23 as a biomarker, therapeutic and diagnostic target
EP2097094A4 (en) 2006-11-01 2011-01-05 George Mason Intellectual Prop BIOMARKERS FOR NEUROLOGICAL SUFFERING
US20100169988A1 (en) 2006-12-06 2010-07-01 Bernhard Kohli Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
WO2008085024A1 (en) 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
JP2010517540A (ja) 2007-02-08 2010-05-27 ポウムリ リミテッド 神経変性疾患の診断法
WO2008100596A2 (en) 2007-02-15 2008-08-21 Burnham Institute For Medical Research Biomarkers of neurodegenerative disease
WO2008102380A1 (en) 2007-02-21 2008-08-28 Decode Genetics Ehf Genetic susceptibility variants associated with cardiovascular disease
CA2682516A1 (en) 2007-03-26 2008-10-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Schizophrenia-related isoform of kcnh2 and development of antipsychotic drugs
JP5555846B2 (ja) 2007-03-30 2014-07-23 国立大学法人山口大学 急性中枢神経障害の予後判定方法
PL390236A1 (pl) 2007-04-12 2010-07-05 Apitope International Nvapitope International Nv Biomarkery stwardnienia rozsianego
GB0708075D0 (en) 2007-04-26 2007-06-06 Univ Nottingham Nethods
WO2008137586A1 (en) 2007-05-01 2008-11-13 University Of Miami Transcriptomic biomarkers for individual risk assessment in new onset heart failure
ITRM20070351A1 (it) 2007-06-22 2008-12-23 Istituto Naz Per Le Malattie I Gene codificante la proteina ambra 1 avente attivita' regolatoria dell autofagia e dello sviluppo del sistema nervoso centrale
WO2009000520A1 (en) 2007-06-25 2008-12-31 Universität Duisburg-Essen Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders
EP2167961A4 (en) 2007-06-27 2010-07-21 Univ Leland Stanford Junior BETA2-MICROGLOBULIN AND C-REACTIVE PROTEIN (CRP) AS BIOMARKERS FOR PERIPHERAL ARTERY DISEASE
FR2918329B1 (fr) 2007-07-06 2009-10-02 Renault Sas Ecope de refroidissement pour vehicule automobile
MX341954B (es) 2007-07-17 2016-09-08 Metabolon Inc Biomarcadores para prediabetes, enfermedades cardiovasculares y otros transtornos relacionados con sindrome metabolico, y metodos de uso de los mismos.
US20090275046A1 (en) 2007-08-29 2009-11-05 Power3 Medical Products, Inc. Complement factor H protein as a biomarker of Parkinson's disease
WO2009032722A1 (en) 2007-08-29 2009-03-12 The Cleveland Clinic Foundation Carbamylated proteins and risk of cardiovascular disease
GB0717637D0 (en) 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
US8609347B2 (en) 2007-10-22 2013-12-17 The Regents Of The University Of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
FI20070795A0 (fi) 2007-10-24 2007-10-24 Faron Pharmaceuticals Oy Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
WO2009058168A1 (en) 2007-11-04 2009-05-07 Prediction Sciences Llc Cellular fibronectin as a diagnostic marker in cardiovascular disease and methods of use thereof
US20100255485A1 (en) 2007-11-28 2010-10-07 Pico Caroni Biomarkers for the onset of neurodegenerative diseases
US8506933B2 (en) 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
WO2009074331A2 (en) 2007-12-11 2009-06-18 Julius-Maximilians-Universität Würzburg Early and differential diagnosis test for alzheimer's disease
WO2009075566A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
EA201400710A1 (ru) * 2008-01-18 2015-03-31 Президент Энд Феллоуз Оф Гарвард Колледж Способы детекции признаков заболеваний или состояний в жидкостях организма
AU2009207923A1 (en) 2008-01-23 2009-07-30 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker YKL-40
WO2009097450A1 (en) 2008-01-30 2009-08-06 Dexcom. Inc. Continuous cardiac marker sensor system
US20110082203A1 (en) 2008-02-04 2011-04-07 Kevin Ka-Wang Wang Process to diagnose or treat brain injury
AU2008255192A1 (en) 2008-03-22 2009-10-08 Newcastle Innovation Limited Detection of a biomarker of aberrant cells of neuroectodermal origin in a body fluid
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
EP2107377A1 (en) 2008-04-04 2009-10-07 BRAHMS Aktiengesellschaft Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events
US8030097B2 (en) 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
WO2010005750A2 (en) 2008-06-16 2010-01-14 The Regents Of The University Of California Potential prognostic markers and therapeutic targets for neurological disorders
US20100167937A1 (en) 2008-07-08 2010-07-01 Power3 Medical Products, Inc. Multiple forms of Alzheimer's disease based on differences in concentrations of protein biomarkers in blood serum
US20110177509A1 (en) 2008-07-23 2011-07-21 The Washington University Risk factors and a therapeutic target for neurodegenerative disorders
US20110143375A1 (en) 2008-08-11 2011-06-16 Banyan Blomakers, Inc. Biomarker detection process and assay of neurological condition
US20100124756A1 (en) 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
GB0818650D0 (en) 2008-10-10 2008-11-19 Uni I Oslo Methods
EP2350643A4 (en) 2008-11-11 2012-06-27 Entelos Inc BIOMARKERS FOR ASSESSING ATHEROSCLEROTIC POTENTIAL
US20120094295A1 (en) 2008-11-21 2012-04-19 The Johns Hopkins University Neurodegenerative disease diagnostic compositions and methods of use
IT1392551B1 (it) 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
AU2009326857B2 (en) 2008-12-09 2016-05-26 Stephanie Fryar-Williams Novel biomarkers
US8563242B2 (en) * 2009-08-11 2013-10-22 The Chinese University Of Hong Kong Method for detecting chromosomal aneuploidy
KR20130041961A (ko) * 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액에서 질환 또는 상태의 특징을 검출하는 방법
EP2596353A4 (en) * 2010-07-23 2014-01-15 Harvard College METHOD FOR DETECTING PRENATAL OR PREGNANT DISEASES OR SUFFERING

Also Published As

Publication number Publication date
US20180245158A1 (en) 2018-08-30
CA2876731A1 (en) 2013-12-19
JP2015522260A (ja) 2015-08-06
WO2013188846A1 (en) 2013-12-19
AU2013274002A1 (en) 2015-02-05
HK1209793A1 (en) 2016-04-08
EP2861765B1 (en) 2019-01-23
MX2014015425A (es) 2015-07-14
CN104603289A (zh) 2015-05-06
SG11201408385TA (en) 2015-01-29
SG10201610508VA (en) 2017-02-27
KR20150035821A (ko) 2015-04-07
US20140179805A1 (en) 2014-06-26
EP2861765A4 (en) 2016-03-16
EP2861765A1 (en) 2015-04-22
BR112014031365A2 (pt) 2017-06-27
IL236181A0 (en) 2015-01-29
US20150275298A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
EA201590027A1 (ru) Способы детекции заболеваний или состояний
EA201390149A1 (ru) Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток
IL246060B (en) Biosensors for biological or chemical analysis and methods of manufacturing the same
GB201305223D0 (en) Reflection detection type measurement apparatus for skin autofluorescence
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
EP3004385A4 (en) Nanopore-based nucleic acid analysis with mixed fret detection
GB2526736A (en) Methods, compositions, and kits for nucleic acid analysis
GB2519906A (en) Methods and systems for detecting biological components
EA201391245A1 (ru) Интеррогативные клеточные анализы и их применение
MX356986B (es) Metodo para detectar aductos de nucleosomas.
BR112014018831A2 (pt) método para otimizar sensibilidade e/ou seletividade de um sensor para um ou mais analitos, método para formar um sensor para um ou mais analitos, kit para a detecção de um ou mais analitos, método de identificação de um aptâmero, composição de matéria e aptâmeros.
BR112014018995A2 (pt) Sistemas para executar ensaio automatizado
WO2013039477A8 (en) Non-invasive methods of detecting target molecules
ITRM20120383A1 (it) Metodo e kit per la rivelazione di anticorpi.
MX365061B (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
IN2014DN04645A (ru)
EP2972219A4 (en) AUTOMATED REAGENT MANAGER OF A DIAGNOSTIC ANALYZER SYSTEM
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
GB201206977D0 (en) An enzyme detection device
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
SG10201907690TA (en) Device and method for detecting target molecules